Core Insights - The launch of the "Beijing Universal Health Insurance" for 2026 includes the first and only approved stem cell drug in China, Amy Maitosai Injection, which significantly reduces the financial burden on severe patients by offering up to 65% reimbursement for treatment [1][2] - The inclusion of Amy Maitosai in the special drug directory expands the coverage and depth of advanced biological therapy technologies in the country, facilitating the commercialization process of cell therapy [1] Group 1 - The drug Amy Maitosai Injection is developed by domestic company PlasBio and is indicated for acute graft-versus-host disease (aGVHD) in patients over 14 years old who have failed hormone treatment [1] - aGVHD is one of the most severe complications following hematopoietic stem cell transplantation, with limited traditional treatment options and low long-term survival rates for patients unresponsive to hormone therapy [1] Group 2 - The pricing of Amy Maitosai Injection is significantly lower than its US counterpart, Ryoncil, with a cost of 19,000 RMB per bag compared to 190,000 USD per treatment, making it more accessible [2] - The drug has been rapidly adopted across China, with appointment services available in over 20 provinces, and its distribution covering more than half of the provinces nationwide [2] - Ongoing clinical research is being conducted to expand the indications for Amy Maitosai, targeting difficult-to-treat immune and inflammatory diseases such as diabetic nephropathy and vascular aging, potentially benefiting a broader patient population in the future [2]

Core Insights - The first and only approved stem cell drug in China, Aimi Maitosai Injection, has made significant progress with its first prescription issued in Beijing, marking the start of its commercial clinical application [1] - The drug, developed by domestic company Platinum Bio, is aimed at treating acute graft-versus-host disease (aGVHD) in patients over 14 years old who have failed hormone therapy [1] - The cost of Aimi Maitosai Injection is approximately 20,000 RMB per bag, significantly lower than similar products in the US, which are priced at 190,000 USD per bag, thus reducing the financial burden on patients [1] Product Development and Market Expansion - Aimi Maitosai Injection has transitioned the treatment of aGVHD from a single-target approach to a multi-target and multi-pathway treatment strategy [1] - The drug's service has achieved nationwide coverage in China, facilitated by strategic partner Alibaba Health, with appointment services available in over 20 provinces including Beijing, Shanghai, and Guangdong [1] - Ongoing research is being conducted to expand the drug's indications to include diabetic nephropathy, acute kidney injury, and vascular aging, potentially broadening its application in various disease areas [1]